Atlas Trials

B-cell Lymphoma Recurrent

17 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch B-cell Lymphoma Recurrent

RecordFirmDate
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (NCT05318963)Institute of Hematology & Blood Diseases Hospital, China2022-03-14
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation (NCT04531046)The Lymphoma Academic Research Organisation2021-03-10
Induced-T Cell Like NK Cells for B Cell Malignancies (NCT04747093)Nanfang Hospital, Southern Medical University2021-01-29
CAR T Cell Therapy Related Cardiovascular Outcomes (NCT05130489)University College London Hospitals2021-01-18
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma (NCT04304040)Beijing InnoCare Pharma Tech Co., Ltd.2020-07-28
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL (NCT04303247)Xinqiao Hospital of Chongqing2020-05-01
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies (NCT04214886)Loyola University2019-12-31
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) (NCT03853616)Miltenyi Biomedicine GmbH2018-11-26
MB-CART20.1 Lymphoma (NCT03664635)Miltenyi Biomedicine GmbH2018-09-25
Combination of Rituximab and NK Immunotherapy for B Lymphoma (NCT02843061)Fuda Cancer Hospital, Guangzhou2016-07-01

Track B-cell Lymphoma Recurrent automatically

Every clearance here is in the API, with alerts when new ones post.